FI920450A0 - Metoder och kompositioner foer foerhindrande av symtomer av sepsis. - Google Patents

Metoder och kompositioner foer foerhindrande av symtomer av sepsis.

Info

Publication number
FI920450A0
FI920450A0 FI920450A FI920450A FI920450A0 FI 920450 A0 FI920450 A0 FI 920450A0 FI 920450 A FI920450 A FI 920450A FI 920450 A FI920450 A FI 920450A FI 920450 A0 FI920450 A0 FI 920450A0
Authority
FI
Finland
Prior art keywords
sepsis
symtomer
synthesis
over composition
antibody molecules
Prior art date
Application number
FI920450A
Other languages
English (en)
Finnish (fi)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Original Assignee
Scripps Clinic Res
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res, Univ Rockefeller filed Critical Scripps Clinic Res
Publication of FI920450A0 publication Critical patent/FI920450A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
FI920450A 1989-08-01 1992-01-31 Metoder och kompositioner foer foerhindrande av symtomer av sepsis. FI920450A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01
PCT/US1990/004250 WO1991001639A1 (fr) 1989-08-01 1990-07-30 Procedes et compositions ameliorant les symptomes de la septicemie

Publications (1)

Publication Number Publication Date
FI920450A0 true FI920450A0 (fi) 1992-01-31

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920450A FI920450A0 (fi) 1989-08-01 1992-01-31 Metoder och kompositioner foer foerhindrande av symtomer av sepsis.

Country Status (14)

Country Link
US (4) US5730980A (fr)
EP (1) EP0485430B1 (fr)
JP (1) JP2744130B2 (fr)
AT (1) ATE171042T1 (fr)
AU (1) AU645515B2 (fr)
CA (1) CA2022429C (fr)
DE (1) DE69032662T2 (fr)
DK (1) DK0485430T3 (fr)
ES (1) ES2120948T3 (fr)
FI (1) FI920450A0 (fr)
GR (1) GR1003164B (fr)
IE (1) IE902770A1 (fr)
PT (1) PT94869B (fr)
WO (1) WO1991001639A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
EP0634935A4 (fr) * 1992-04-06 1996-01-31 North Shore Univ Hospital Nouvelle therapie permettant de traiter la septicemie a l'aide d'une forme soluble de l'antigene myelomonocytique cd14 recombine.
EP0751962B1 (fr) * 1993-05-28 2006-08-02 The Scripps Research Institute Procedes d'inhibition de l'activation des cellules induites par cd14
WO1995000641A1 (fr) * 1993-06-17 1995-01-05 Xoma Corporation Derives de la proteine de liaison du lipopolysaccharide
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ES2255708T3 (es) 1994-09-16 2006-07-01 The Scripps Research Institute Uso de anticuerpos para bloquear los efectos de las bacterias gram-positivas y las micobacterias.
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
EP0793677A1 (fr) * 1994-12-30 1997-09-10 Amgen Inc. Polypeptides cd14 anti-inflammatoires
WO1996032418A1 (fr) * 1995-04-13 1996-10-17 Laboratoires Om S.A. Anticorps anti-cd14 utilises dans l'induction de la secretion il-10
WO1997000081A1 (fr) * 1995-06-19 1997-01-03 Goyert Sanna M Procede empechant la septicemie et la dissemination des bacteries
NZ332720A (en) * 1996-05-10 2000-07-28 Xoma Corp Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
WO1999039704A1 (fr) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Agents antibacteriens
PL345208A1 (en) * 1998-05-27 2001-12-03 Gemma Biotechnology Ltd The induction of antiobiotic proteins and peptides by lait/scd14-protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
WO2001022085A1 (fr) * 1999-09-17 2001-03-29 Mochida Pharmaceutical Co., Ltd. Procede de mesure fractionnel de proteine de cd14 soluble
WO2002042333A1 (fr) * 2000-11-22 2002-05-30 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-cd14 exerçant un effet d'inhibition de la fixation cd14/tlr
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP2008522583A (ja) * 2002-06-14 2008-07-03 セントカー・インコーポレーテツド 修飾“ｓ”抗体
EP2266606B1 (fr) * 2003-05-15 2014-09-10 Genentech, Inc. Méthodes et compositions pour la prévention et traitement du sepsis
WO2006093794A1 (fr) * 2005-02-28 2006-09-08 Centocor, Inc. Compositions de liaison proteinique de forme heterodimerique
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
WO2015140591A1 (fr) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anticorps anti-cd14 et leurs utilisations
AU2018255489B2 (en) * 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis

Also Published As

Publication number Publication date
US20020034509A1 (en) 2002-03-21
PT94869B (pt) 1997-04-30
ES2120948T3 (es) 1998-11-16
WO1991001639A1 (fr) 1991-02-21
US6495332B2 (en) 2002-12-17
US6297049B1 (en) 2001-10-02
US5730980A (en) 1998-03-24
EP0485430A1 (fr) 1992-05-20
JP2744130B2 (ja) 1998-04-28
AU645515B2 (en) 1994-01-20
PT94869A (pt) 1991-04-18
GR900100582A (el) 1991-12-30
EP0485430A4 (en) 1993-03-03
ATE171042T1 (de) 1998-10-15
JPH05501399A (ja) 1993-03-18
EP0485430B1 (fr) 1998-09-16
US6045795A (en) 2000-04-04
CA2022429C (fr) 1998-12-01
DE69032662T2 (de) 1999-03-11
CA2022429A1 (fr) 1991-02-02
AU6146190A (en) 1991-03-11
DK0485430T3 (da) 1999-06-14
IE902770A1 (en) 1991-02-27
GR1003164B (el) 1999-07-05
DE69032662D1 (de) 1998-10-22

Similar Documents

Publication Publication Date Title
FI920450A0 (fi) Metoder och kompositioner foer foerhindrande av symtomer av sepsis.
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
FI930747A (fi) Heterocykliska foereningar och deras framstaellning och anvaendning
FI932561A (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
PT90659A (pt) Process for the manufacture of diol-containing renin inhibitors
FI942345A (fi) Menetelmä proliiniboronaattiesterin valmistamiseksi
DE69526340D1 (de) Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
CA2017025A1 (fr) Proteine de liaison ii du facteur de necrose des tumeurs, sa purification et les anticorps diriges contre elle
DE69132048D1 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
FR2677019B1 (fr) Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
FR2360558A1 (fr) Nouveaux esters de l'epinine, utiles notamment en cardiotherapie, et leur procede de preparation
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
ATE143009T1 (de) Neue heterocyclische carbonsäuren
FR2442852A1 (fr) Nouvelles penicillines et leur application en therapeutique
FR2359153A1 (fr) Nouveaux esters carboxyliques d'acide phosphonoacetique utiles notamment pour le traitement des infections d'herpes simplex
FI911701A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
ES2015349A6 (es) Metodo para producir anticuerpos inmunologicamente reactivos con angiogenina.
NO177710C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive slektede analoger
FR2536387B3 (fr) Procede de fabrication de pierres reconstituees d'apparence vieux granit et pierres obtenues par le procede
FR2303558A1 (fr) Preparation therapeutique pour traiter l'infection sous forme de pneumonie hemorragique du vison et de mastite bovine causees par la pseudomonas aeruginosa
FI911783A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-/3-(4-oksotiatsolidinyyli)/butynyyliamiinien valmistamiseksi
IT1101727B (it) Nuove 2-fenilammino-imidazoline-(2) sostituite, dotate di particolari proprieta' terapeutiche, loro processo di sintesi e composizioni farmaceutiche

Legal Events

Date Code Title Description
FD Application lapsed